Phenotypic profiling in pancreatic cancer: promise meets practical limits
COMPASS trial suggests that selecting treatment based on subtypes classification may impact patients’ outcomes, but the approach is hard to implement in clinical practice
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Can the benefits of lung cancer screening be extended to never-smokers?
Recent data provide further evidence that non-risk-based screening can improve survival if biomarkers can be identified to target screening to those at the highest risk
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Combining the optimisation of clinical pathways with tumour molecular insights enables more accurate and personalised cancer care
From bispecific to multispecific antibodies: a highly promising field
Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles
Redesigning oncology clinical trials with agentic AI
Semi-autonomous and autonomous foundation models are helping cancer research and anticancer drug development
The challenge of undifferentiated sarcomas
Recent studies have improved current understanding of clinical variability and molecular diversity of this subgroup, but many questions remain
Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
The power of dual-layer genomics in precision oncology
Integrating DNA and RNA profiling is a promising approach to advance cancer characterisation and guide clinical decision-making